Limits...
Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.

Hsu LH, Liu KJ, Tsai MF, Wu CR, Feng AC, Chu NM, Kao SH - Cancer Sci. (2014)

Bottom Line: We found that the premenopausal patients had more advanced disease and a shorter survival among the never-smoking female patients with lung adenocarcinoma.We proposed a different pathway that estrogen upregulated the expression of osteopontin and then promoted cell migration through αvβ3 integrin binding and activated MEK-ERK signaling pathway, which is a common downstream pathway with epidermal growth factor receptor (EGFR) activation.An additive effect of ER antagonists and EGFR antagonists on the inhibition of cell migration was also noted.

View Article: PubMed Central - PubMed

Affiliation: Division of Pulmonary and Critical Care Medicine, Sun Yat-Sen Cancer Center, Taipei, Taiwan; Department of Medicine, National Yang-Ming University Medical School, Taipei, Taiwan.

Show MeSH

Related in: MedlinePlus

Both estrogen and osteopontin (OPN) were elevated and positively correlated in the malignant pleural effusions from the patients with lung adenocarcinoma. (a,b) Wound healing assay of A549 or PE089 cells incubated for 24 h with the cell-free supernatants of malignant pleural effusions (PE) from a patient with lung adenocarcinoma. Tamoxifen and/or gefitinib inhibited the cell migration induced by the malignant pleural effusion. *P < 0.05 compared with the control. (c) Estradiol and OPN were both elevated and positively correlated in the malignant pleural effusions from the 62 female patients with lung adenocarcinoma. (d) Schematic diagram illustrating the proposed mechanism of how estrogen affects lung cancer cell migration. Estrogen upregulates OPN expression and promotes lung cancer cell migration via the MEK/ERK signaling pathway. OPN contributes to the cross-talk between ER and EGFR signaling pathways.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317775&req=5

fig05: Both estrogen and osteopontin (OPN) were elevated and positively correlated in the malignant pleural effusions from the patients with lung adenocarcinoma. (a,b) Wound healing assay of A549 or PE089 cells incubated for 24 h with the cell-free supernatants of malignant pleural effusions (PE) from a patient with lung adenocarcinoma. Tamoxifen and/or gefitinib inhibited the cell migration induced by the malignant pleural effusion. *P < 0.05 compared with the control. (c) Estradiol and OPN were both elevated and positively correlated in the malignant pleural effusions from the 62 female patients with lung adenocarcinoma. (d) Schematic diagram illustrating the proposed mechanism of how estrogen affects lung cancer cell migration. Estrogen upregulates OPN expression and promotes lung cancer cell migration via the MEK/ERK signaling pathway. OPN contributes to the cross-talk between ER and EGFR signaling pathways.

Mentions: To investigate whether the cell-free supernatants of malignant pleural effusions provide a migratory niche for A549 or PE089 cells, the cells were incubated with the malignant pleural effusions from patients with lung adenocarcinoma (n = 24). In Figure5a, the wound healing assays were treated with the malignant pleural effusion from a female never-smoker patient with lung adenocarcinoma harboring an EGFR exon 21 L858R mutation. We found that the malignant pleural effusions more intensely promoted cell migration than E2 or EGF. Additive inhibition of the malignant pleural effusion-induced cell migration was found with tamoxifen and gefitinib supplementations (Fig.5a,b). Patients with malignant pleural effusion had higher pleural fluid E2 (median, 13.0 vs 10.0 pg/mL; P = 0.085) and OPN (median, 318.77 vs 256.28 ng/mL; P = 0.289) concentrations than those with non-malignant pleural effusion, although statistical significance was not reached. The premenopausal women had higher pleural fluid E2 (median, 21.5 vs 13.0 pg/mL; P = 0.044) concentrations than the postmenopausal women. Pleural fluid E2 and OPN concentrations were positively correlated (n = 62, r = 0.74, P = 0.002; Fig.5c).


Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.

Hsu LH, Liu KJ, Tsai MF, Wu CR, Feng AC, Chu NM, Kao SH - Cancer Sci. (2014)

Both estrogen and osteopontin (OPN) were elevated and positively correlated in the malignant pleural effusions from the patients with lung adenocarcinoma. (a,b) Wound healing assay of A549 or PE089 cells incubated for 24 h with the cell-free supernatants of malignant pleural effusions (PE) from a patient with lung adenocarcinoma. Tamoxifen and/or gefitinib inhibited the cell migration induced by the malignant pleural effusion. *P < 0.05 compared with the control. (c) Estradiol and OPN were both elevated and positively correlated in the malignant pleural effusions from the 62 female patients with lung adenocarcinoma. (d) Schematic diagram illustrating the proposed mechanism of how estrogen affects lung cancer cell migration. Estrogen upregulates OPN expression and promotes lung cancer cell migration via the MEK/ERK signaling pathway. OPN contributes to the cross-talk between ER and EGFR signaling pathways.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317775&req=5

fig05: Both estrogen and osteopontin (OPN) were elevated and positively correlated in the malignant pleural effusions from the patients with lung adenocarcinoma. (a,b) Wound healing assay of A549 or PE089 cells incubated for 24 h with the cell-free supernatants of malignant pleural effusions (PE) from a patient with lung adenocarcinoma. Tamoxifen and/or gefitinib inhibited the cell migration induced by the malignant pleural effusion. *P < 0.05 compared with the control. (c) Estradiol and OPN were both elevated and positively correlated in the malignant pleural effusions from the 62 female patients with lung adenocarcinoma. (d) Schematic diagram illustrating the proposed mechanism of how estrogen affects lung cancer cell migration. Estrogen upregulates OPN expression and promotes lung cancer cell migration via the MEK/ERK signaling pathway. OPN contributes to the cross-talk between ER and EGFR signaling pathways.
Mentions: To investigate whether the cell-free supernatants of malignant pleural effusions provide a migratory niche for A549 or PE089 cells, the cells were incubated with the malignant pleural effusions from patients with lung adenocarcinoma (n = 24). In Figure5a, the wound healing assays were treated with the malignant pleural effusion from a female never-smoker patient with lung adenocarcinoma harboring an EGFR exon 21 L858R mutation. We found that the malignant pleural effusions more intensely promoted cell migration than E2 or EGF. Additive inhibition of the malignant pleural effusion-induced cell migration was found with tamoxifen and gefitinib supplementations (Fig.5a,b). Patients with malignant pleural effusion had higher pleural fluid E2 (median, 13.0 vs 10.0 pg/mL; P = 0.085) and OPN (median, 318.77 vs 256.28 ng/mL; P = 0.289) concentrations than those with non-malignant pleural effusion, although statistical significance was not reached. The premenopausal women had higher pleural fluid E2 (median, 21.5 vs 13.0 pg/mL; P = 0.044) concentrations than the postmenopausal women. Pleural fluid E2 and OPN concentrations were positively correlated (n = 62, r = 0.74, P = 0.002; Fig.5c).

Bottom Line: We found that the premenopausal patients had more advanced disease and a shorter survival among the never-smoking female patients with lung adenocarcinoma.We proposed a different pathway that estrogen upregulated the expression of osteopontin and then promoted cell migration through αvβ3 integrin binding and activated MEK-ERK signaling pathway, which is a common downstream pathway with epidermal growth factor receptor (EGFR) activation.An additive effect of ER antagonists and EGFR antagonists on the inhibition of cell migration was also noted.

View Article: PubMed Central - PubMed

Affiliation: Division of Pulmonary and Critical Care Medicine, Sun Yat-Sen Cancer Center, Taipei, Taiwan; Department of Medicine, National Yang-Ming University Medical School, Taipei, Taiwan.

Show MeSH
Related in: MedlinePlus